NAD+
NAD+ (nicotinamide adenine dinucleotide) is a critical coenzyme involved in cellular energy metabolism, DNA repair, and mitochondrial function. Clinical research has primarily employed intravenous infusions at high doses, though subcutaneous administration at lower doses is emerging as a practical maintenance route. This educational protocol presents a once‑daily subcutaneous approach with gradual titration for improved tolerability.
Reconstitution Steps
Allow the lyophilized vial to reach room temperature before opening to minimize moisture condensation.
Draw 3.0 mL bacteriostatic water (0.9% benzyl alcohol) with a sterile syringe.
Inject slowly down the vial wall to avoid foaming; do not aim directly at the powder.
Gently swirl or roll the vial until the powder fully dissolves (do not shake vigorously).
The resulting solution should be clear and colorless. If discoloration or precipitate appears, discard.
Label with the reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Use within 14 days; inspect before each use for clarity.
Note: Each 0.01 mL (1 unit) contains approximately 3.33 mg of NAD+. Example conversions: 50 mg = 15 units; 75 mg = 22.5 units; 100 mg = 30 units.
Protocol Overview
Concise summary of the once-daily regimen based on clinical trial designs.
Goal: Support cellular energy metabolism, DNA repair pathways, and mitochondrial function through exogenous NAD+ supplementation
Schedule: Daily subcutaneous injections for 8–16 weeks with gradual dose titration.
Dose Range: 50–100 mg daily; start low (50 mg) and increase by ~25 mg weekly as tolerated.
Reconstitution: 3.0 mL per 1000 mg vial (333.3 mg/mL) for accurate unit measurements.
Storage: Lyophilized powder frozen at −20 °C (−4 °F); reconstituted solution refrigerated at 2–8 °C (35.6–46.4 °F) for up to 14 days; protect from light.
Dosing Protocol
Suggested daily titration approach reflecting clinical study parameters.
Start: 50 mg daily for Week 1 to assess individual tolerance.
Escalation: Increase by 25 mg in Week 2 (75 mg daily); advance to 100 mg daily by Week 3 if well‑tolerated.
Maintenance: Continue at 100 mg daily for Weeks 3–16 (or adjust based on response and tolerability).
Frequency: Once per day, subcutaneous injection.
Timing: Any consistent time of day; some users prefer morning administration.
Site Rotation: Rotate injection sites systematically (abdomen, thighs, upper arms) to prevent tissue buildup.
Storage Instructions
Proper storage preserves peptide quality.
Lyophilized (Unopened): Store at −20 °C (−4 °F) or below (ideally −80 °C for multi‑year storage) in a dry, dark environment. Minimize moisture exposure as NAD+ powder is hygroscopic.
Reconstituted Solution: Refrigerate at 2–8 °C (35.6–46.4 °F) and use within approximately 28 days. Keep protected from light (UV exposure degrades NAD+).
Avoid Freeze–Thaw Cycles: Do not repeatedly freeze and thaw reconstituted NAD+ solution, as this reduces potency.
Inspection: Before each use, inspect the solution for clarity. A fresh NAD+ solution should be clear and colorless. Discard if discoloration, cloudiness, or precipitate develops.
Important Notes
Practical considerations for consistency and safety.
Use new, sterile insulin syringes for each injection; dispose of used needles in a proper sharps container.
Rotate injection sites systematically (abdomen at least 2 inches from navel, outer thighs, back of upper arms) to reduce soreness and prevent lipohypertrophy.
Clean both the vial stopper and injection site with alcohol swabs; allow skin to air‑dry before injecting.
Inject slowly over 5–10 seconds to minimize tissue irritation; wait a few seconds before withdrawing the needle.
Document daily dose, injection site, and any observed effects to maintain consistency and track tolerance.
If persistent redness or a lump develops at injection sites, apply over‑the‑counter hydrocortisone cream and rotate to a different location.
Starting at the low end (50 mg) is recommended to assess individual tolerance before escalating dose.
How This Works
NAD+ is a coenzyme central to redox reactions, energy metabolism (glycolysis, TCA cycle, oxidative phosphorylation), and cellular maintenance pathways including DNA repair and mitochondrial biogenesis. Cellular NAD+ levels decline with age and metabolic stress, which may contribute to reduced mitochondrial function and impaired cellular resilience.
Clinical research on NAD+ therapy has primarily used intravenous infusions at high doses (500–1,000 mg) for applications such as addiction treatment and acute metabolic support. A pilot metabolic study demonstrated that a 750 mg NAD+ IV infusion over 6 hours was well‑tolerated in humans, with rapid metabolic clearance and no acute toxicity. However, IV administration requires clinical supervision and specialized equipment.
Subcutaneous (SC) or intramuscular (IM) injections at lower doses (tens to low hundreds of milligrams) are emerging as practical alternatives for maintenance therapy and wellness applications. Compounded NAD+ can be administered SC in small volumes, and SC self‑injection is convenient for ongoing use. Conservative protocols start around 50–100 mg per injection a few times per week; the present protocol uses daily SC administration with gradual titration to optimize individual tolerance and response.
Potential Benefits
May support cellular energy production and mitochondrial function through replenishment of NAD+ pools.
Human case reports and pilot studies suggest benefits at 100–300 mg/day ranges for cognitive support and metabolic health.
High‑dose IV protocols (500–1,500 mg daily for ~10 days) have been used in open‑label studies for substance use disorder, with reports of reduced cravings and improved mood in follow‑ups.
No severe adverse events have been reported in published NAD+/NADH trials; side effects are generally mild.
Potential Side Effects
High doses can produce adverse reactions such as insomnia, anxiety, or fatigue if escalated too quickly; gradual titration is advised.
Mild injection‑site reactions (redness, itching, soreness) may occur with subcutaneous administration; typically resolve with site rotation.
Some individuals report transient headache or flushing; these effects are generally dose‑dependent.
Doses exceeding ~200–300 mg/day should generally be reserved for supervised therapeutic use due to potential for metabolic byproduct accumulation.
Lifestyle Factors
Complementary strategies that may support therapeutic goals.
Nutrition: Consume a balanced diet rich in NAD+ precursors (niacin/vitamin B3, tryptophan) and support nutrients (B‑vitamins, magnesium). Consider foods that support methylation pathways.
Exercise: Regular physical activity (both resistance training and aerobic exercise) naturally upregulates cellular NAD+ biosynthesis and enhances mitochondrial adaptations.
Sleep: Prioritize 7–9 hours of quality sleep per night to support cellular repair processes and optimize circadian NAD+ metabolism.
Stress Management: Chronic stress depletes NAD+ pools through activation of poly(ADP‑ribose) polymerases (PARPs); incorporate stress‑reduction practices like meditation or yoga.
Avoid Excessive Alcohol: Alcohol metabolism consumes NAD+; moderate or eliminate alcohol intake during NAD+ protocols.
